Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 12 Show results per page	View Search Criteria \| Help With Results

Last Modified: 3/1/2002


1.		Phase III Randomized Study of Marimastat (a Matrix Metalloproteinase Inhibitor) vs Gemcitabine as First-Line Therapy for Pancreatic Cancer (Summary Last Modified 03/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				BB-C03/IVB/128 NCI-V96-0908

Last Modified: 6/1/1999


2.		Phase III Randomized Study of Marimastat (a Matrix Metalloproteinase Inhibitor) in Glioblastoma Multiforme or Gliosarcoma Following Completion of Conventional First-Line Treatment (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Supportive care, Treatment				Completed				18 and over				Pharmaceutical / Industry				BB-C03/IVB/131 NCI-V96-0909

Last Modified: 3/1/2002


3.		Phase III Randomized, Double Blind, Placebo Controlled Study of Marimastat (a Matrix Metalloproteinase Inhibitor) in Small Cell Lung Cancer Responsive to First Line Chemotherapy (Summary Last Modified 03/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				BB-C03/IVB/140 NCI-V96-0910

Last Modified: 5/14/2007


4.		Phase III Randomized Study of Marimastat (a Matrix Metalloproteinase Inhibitor) in Patients with Minimal Disease Stage III Non-Small Cell Lung Cancer (Summary Last Modified 03/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				18 and over				Pharmaceutical / Industry				ILEX-C03-IVB/173 BB-C03-IVB/173, NCI-V96-1113, NCT00002911

Last Modified: 5/14/2007 First Published: 7/1/1997


5.		Phase III Randomized Study of Marimastat versus Placebo in Women with Metastatic Breast Cancer Who Have Responding or Stable Disease After Induction Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Closed				18 and over				NCI				E-2196 NCCTG-E2196, NCT00003010, E2196

Last Modified: 5/14/2007 First Published: 6/1/1997


6.		Phase III Randomized Study of Marimastat in Patients with Small Cell Lung Cancer Following a Response to First Line Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase III				Treatment				Completed				16 and over								EORTC-08962 CAN-NCIC-BR12, EORTC-08962B, NCT00003011, BR12

Last Modified: 6/1/1999


7.		Phase I/II Study of BB-2516 (a Matrix Metalloproteinase Inhibitor) for Advanced Pancreatic Cancer (Summary Last Modified 06/1999)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over				Pharmaceutical / Industry				MSKCC-95044A1 NCI-V95-0751

Last Modified: 3/1/2002


8.		Phase I/II Study of Marimastat for Advanced Melanoma (Summary Last Modified 03/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Completed				18 and over								CAN-NCIC-IND91 NCI-V95-0757, IND91

Last Modified: 3/1/2002


9.		Phase II Study of Gamma Knife Radiosurgery and Marimastat (BB-2516) in Patients With Recurrent Malignant Glioma (Summary Last Modified 03/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				Over 18				Pharmaceutical / Industry				BB-C03-IVB-172 NCI-V96-1112

Last Modified: 3/1/2002 First Published: 11/1/1997


10.		Phase II Open Label Pilot Study of Adjuvant Marimastat in Patients with Early Stage Breast Cancer (Summary Last Modified 03/2002)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				BB-C03/IVB/185 NCI-V97-1265

Select All on One Page


					1 2 Next >

| | | | | | | |

A Service of the National Cancer Institute